-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $50

Benzinga·10/07/2026 11:22:03
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $50.